The battle against bacterial infections and the diseases they cause is one sadly where the bacteria are becoming stronger and the human is becoming weaker. Bacteria constantly are able to mutate to become resistance to the defense mechanisms such as antibiotics that we put into our body. According to the CDC 2019 Antibiotic Resistance Report more than 2.8 million antibiotic infections occur in the US and more than 35,000 people die in response. A rise in resistant infection puts more people at risk and threatens the progress antibiotics have made in healthcare. As more people are exposed to antibiotics bacteria are more capable to gain resistance to those drugs causing a continuous rush and need for the development for new antibiotics. Yet these bacteria are able to obtain resistance faster than we can develop drugs. Bacteria are now one step ahead of us, as we used to be one step ahead from them. This is a foot race to combat these fatal infections and propel the healthcare industry.
The CDC divides the prevalent resistant microbes into three categories in regard to threat to humans: Urgent Threats, Serious Threats, Concerning Threats. There is a watch list for bacteria that is on the verge of becoming a major resistance threat, however it is important to focus on these as well to avoid further resistance development. C. difficile is on the Urgent Threat list, there are approximately 223,900 infections per year and 12,800 per year. C. difficile is a superbug which is a strain of bacteria that is resistant to several types of antibiotics. C. difficile is present in the gut microbial but as antibiotics are used to treat other infections it can attack the healthy microbial and allow the C. difficile to become activated. C. difficile is a double whammy as it is developing increased antibiotic resistance and is also caused by the use of antibiotics. Antibiotics can make infected persons sicker because they kill the C. Difficile but also the good bacteria that keep the C. Difficile in balance which allows C. Difficile to grow without competition. C. Difficile is now one of the three top superbugs identified by the CDC.
C. Difficile is also is hard to kill by disinfectants so if C. Difficile is on surfaces in hospitals the hospital grade disinfectants are unable to kill it. This gives opportunity to develop not just antibiotics to fight the super bug but rise to disinfectants that can combat super bugs. Because often these infections are spread from surface contact, so combating them from transmitting is one way to eliminate a super bug all together. It is important that the drug development and healthcare industries look beyond medication development to fight off superbugs. They need to be innovative and work to kill the superbugs off of the surfaces where they are transmitted such as in hospitals and nursing homes. We need to combat these superbugs where they least expect it and it is in environments where they are weaker which is on exposed surfaces before they are transmitted into the human body where they can thrive and replicate without competition.
The number of those infected by resistant bacteria is only going to increase if we do not work to improve the lifespan of antibiotics. At this point, time is not on our side as bacteria are able to evolve resistance early of development. It is crucial to get ahead of the bacteria before we have no proper medication to combat bacterial infections. A way to achieve this is to reduce human dependence on medications and relying on antibiotics to be a “quick fix” to their infections even when they might not even have a bacterial infection. As humans increase their exposure to antibiotics bacteria increase their resistance. This direct relationship is why it is crucial for humans to combat these superbugs in unconventional methods.






